d4T: keep it or abandon it?

1. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L, Médecins Sans Frontieres. Generic fixeddose combination antiretroviral treatment in resourcepoor settings: multicentric observational cohort. AIDS. 2006; 20:1163-9.10.1097/01.aids.0000226957.79847.d6Open DOISearch in Google Scholar

2. Ferradini L, Jeannin A, Pinogues L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up highly active antiretroviral therapy in the district of Malawi: an effectiveness assessment. Lancet. 2006; 367: 1335-42.10.1016/S0140-6736(06)68580-2Search in Google Scholar

3. Gallant J, Staszewski S, Pozniak A, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of Tenofovir DF vs Stavudine in combination therapy in antiretroviral naïve patients. JAMA. 2004; 292:191-201.10.1001/jama.292.2.19115249568Search in Google Scholar

4. Stavudine US prescribing information. Bristol Myers Squibb. Available at: www.zerit.com. Accessed November 2006.Search in Google Scholar

5. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother. 2007; 8:1-10.10.1517/14656566.8.5.67917376022Search in Google Scholar

6. World Health Organisation. Addendum to 2006 HIV Treatment Guidelines. Available at: http://www.who.int/hiv/art/ARTadultsaddendum.pdf. Accessed October 2009.Search in Google Scholar

7. Ruxrungtham K, Kroon E, Ungsedhapand C, Teeratakulpisarn S, Ubolyam S, Buranapraditkun S, et al. A randomised, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naïve, HIV-infected Thai patients. AIDS. 2000; 14:1375-82.10.1097/00002030-200007070-0001010930152Open DOISearch in Google Scholar

8. Siangphoe U, Srikaew S, Waiwavaravuth C, Chariyasetphong T, Kamsaw O, Klinbua V, et al. Efficacy and safety of half dose compared to full dose stavudine (d4T) and zidovudine (AZT) in combination with didanosine (ddI) in Thai HIV-infected patients: 96-week results of ACTT002/ARV065 study. Presented at World AIDS Conference, Bangkok, July 2004 [abstr WePeB5952].Search in Google Scholar

9. Ribera E, Paradinero J, Domingo P, Sauleda S, Luque S, Garcia-Arumi E, et al. A randomized study comparing the efficacy and tolerability of low-dose versus standard-dose stavudine in antiretroviral-naïve patients (ETOX study). Presented at 3rd International Conference on AIDS Pathogenesis, Rio de Janiero, Brazil, July 2005 [abstr TuPe2.4c10].Search in Google Scholar

10. UNAIDS, WHO, UNICEF: Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Update 2009. Available on-line at: http://www.who.int/hiv/pub/tuapr_2009_en.pdf. Accessed October 2009.Search in Google Scholar

11. Médecins Sans Frontieres. Untangling the Web of Antiretroviral Price Reductions: A pricing guide for the purchase of ARVs for developing countries. Upcoming 12th Edition - Pre-publication price analysis-July 2009. 1) Available at: http://www.msfaccess.org/fileadmin/user_upload/diseases/hiv-aidsUntangling_the_Web/UntanglingtheWeb12_prepublicationpriceanalysis_July09pdf.pdf. Accessed October 2009.Search in Google Scholar

12. Browne M, Mayer K, Chafee S, Dudley MN, Posner MR, Steinberg SM, et al. 2ʹ, 3ʹ-didehydro-3ʹ- deoxythymidine (d4T) in patients with AIDS or AIDS-related complex. J Inf Dis. 1993, 167: 21-9.10.1093/infdis/167.1.218093363Search in Google Scholar

13. Petersen E, Ramirez-Ronda C, Hardy D, Schwartz R, Sacks HS, Follansbee S, et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Inf Dis. 1995; 171 (Suppl 1): S 131-9.10.1093/infdis/171.Supplement_2.S131Search in Google Scholar

14. Spruance S, Pavia A, Mellors J, Murphy R, Gathe J, Stool E, et al. Clinical Efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine experienced patients in a randomized, double-blind, controlled trial. Bristol-Myers Stavudine 019 Study Group. Ann Intern Med. 1997; 126: 355-63.10.7326/0003-4819-126-5-199703010-000039054279Search in Google Scholar

15. Anderson R, Dunkle L, Smaldone L, Adler M, Wirtz C, Kriesel D, et al. Design and implementation of the stavudine parallel track programme. Comparison of safety and efficacy of two doses of stavudine in a simple trial in the US parallel track programme. J Inf Dis. 1995; 171:118-22.10.1093/infdis/171.Supplement_2.S118Search in Google Scholar

16. Sanchez-Conde M, de Mendoza C, Jimenez-Nacher I, Barriero P, Gonzalenz-Lahoz J, Soriano V. Reductions in stavudine dosage might ameliorate mitochondrialassociated complications without compromising antiviral activity. HIV Clin Trials. 2005; 6:197-202.10.1310/ED57-EU48-RK6A-E5U0Search in Google Scholar

17. Milinkovic A, Martinez E, Lopez S, de Lazzari E, Miro O, Blanco J, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther. 2007; 12:407-12.10.1177/135965350701200301Search in Google Scholar

18. Ait Mohand H, Bonmarchand M, Guiget M, Slama L, Slama L, Marguet F, Behin A, et al. Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study. HIV Med. 2008; 9:738-46.10.1111/j.1468-1293.2008.00616.x18651858Search in Google Scholar

19. Hostede H, Koopmans P, Burger D. Stavudine plasma concentrations and lipoatrophy. J Antimicrob Ag Chemother. 2008; 61:933-8.10.1093/jac/dkn04118281306Search in Google Scholar

20. Clinton HIV-AIDS Initiative. Antiretroviral price list 2009. Available at: http://www.clintonfoundation.org/files/chaiarvpricelistaugust2009english.pdf. Accessed October 2009.Search in Google Scholar

21. Koegl C, Wolf E, Postel N, Ruemmelein N, Postel N, Jaegel-Guedes E, et al. Low dose stavudine: as effective as standard dose but less side effects. Presented at 9th European AIDS Conference (EACS), Warsaw, October 25 2003. [abstract 9.8/5].Search in Google Scholar

22. Hanvanich M, Prasanthai V, Riengchan P, Arunyingmongkol K, Intalapaporn P, Hiransuthikul N, et al. Reduction of d4T dosage improves lipoatrophy without virologic failure. Antiviral Therapy. 2003; 8 (Suppl 1): S392.Search in Google Scholar